PL3426285T3 - Formulacje i dawki pegylowanej urykazy - Google Patents
Formulacje i dawki pegylowanej urykazyInfo
- Publication number
- PL3426285T3 PL3426285T3 PL17715298.0T PL17715298T PL3426285T3 PL 3426285 T3 PL3426285 T3 PL 3426285T3 PL 17715298 T PL17715298 T PL 17715298T PL 3426285 T3 PL3426285 T3 PL 3426285T3
- Authority
- PL
- Poland
- Prior art keywords
- dosages
- pegylated uricase
- formulations
- uricase formulations
- pegylated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662307412P | 2016-03-11 | 2016-03-11 | |
US201662339944P | 2016-05-22 | 2016-05-22 | |
US201662346348P | 2016-06-06 | 2016-06-06 | |
US201662397832P | 2016-09-21 | 2016-09-21 | |
US201662398422P | 2016-09-22 | 2016-09-22 | |
US201662403664P | 2016-10-03 | 2016-10-03 | |
US201662430547P | 2016-12-06 | 2016-12-06 | |
US201762442948P | 2017-01-05 | 2017-01-05 | |
PCT/US2017/021991 WO2017156513A1 (en) | 2016-03-11 | 2017-03-11 | Formulations and doses of pegylated uricase |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3426285T3 true PL3426285T3 (pl) | 2024-12-16 |
Family
ID=58464628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL17715298.0T PL3426285T3 (pl) | 2016-03-11 | 2017-03-11 | Formulacje i dawki pegylowanej urykazy |
Country Status (20)
Country | Link |
---|---|
US (3) | US20170258927A1 (pl) |
EP (2) | EP3426285B1 (pl) |
JP (3) | JP7417354B2 (pl) |
KR (2) | KR20220123332A (pl) |
CN (1) | CN109152819A (pl) |
AU (2) | AU2017230891B2 (pl) |
BR (1) | BR112018068249A2 (pl) |
CA (1) | CA3017365A1 (pl) |
DK (1) | DK3426285T3 (pl) |
ES (1) | ES2986077T3 (pl) |
FI (1) | FI3426285T3 (pl) |
HR (1) | HRP20241127T1 (pl) |
HU (1) | HUE068144T2 (pl) |
IL (2) | IL318183A (pl) |
LT (1) | LT3426285T (pl) |
MX (1) | MX2018011012A (pl) |
PL (1) | PL3426285T3 (pl) |
PT (1) | PT3426285T (pl) |
RS (1) | RS65941B1 (pl) |
WO (1) | WO2017156513A1 (pl) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG161247A1 (en) | 2005-04-11 | 2010-05-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
WO2010151823A1 (en) | 2009-06-25 | 2010-12-29 | Savient Pharmaceuticals Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
WO2012149265A2 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses |
WO2013019648A1 (en) | 2011-07-29 | 2013-02-07 | Selecta Biosciences, Inc. | Control of antibody responses to synthetic nanocarriers |
KR20240119160A (ko) | 2013-05-03 | 2024-08-06 | 셀렉타 바이오사이언시즈, 인크. | 바람직하지 않은 체액성 면역 반응을 감소시키기 위한 투약 조합물 |
AU2015311706A1 (en) | 2014-09-07 | 2017-02-02 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
KR20250011715A (ko) | 2017-03-11 | 2025-01-21 | 셀렉타 바이오사이언시즈, 인크. | 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물 |
CN111373034A (zh) | 2017-07-07 | 2020-07-03 | 艾乐娜制药有限公司 | 重组尿酸酶 |
CN109875988B (zh) * | 2018-09-13 | 2021-08-27 | 江西中医药大学 | 一种化合物dhnb缩氨基脲的合成及其在防治痛风与高尿酸血症的应用 |
US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
JP2022535121A (ja) * | 2019-06-04 | 2022-08-04 | セレクタ バイオサイエンシーズ インコーポレーテッド | ペグ化ウリカーゼの処方物および用量 |
KR102260478B1 (ko) * | 2019-08-19 | 2021-06-02 | 연세대학교 산학협력단 | 일나트륨 요소화물 결정 용해용 조성물 |
WO2021042055A1 (en) * | 2019-08-30 | 2021-03-04 | Horizon Pharma Rheumatology Llc | Pegloticase for treatment of gout in renal transplant recipients |
IL292392A (en) * | 2019-10-21 | 2022-06-01 | Selecta Biosciences Inc | Methods and compositions for treating liver diseases and disorders |
CN115190795A (zh) * | 2019-11-08 | 2022-10-14 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
KR102200329B1 (ko) * | 2019-11-11 | 2021-01-08 | 광주과학기술원 | 반감기 증가를 위한 치료용 단백질-지방산 접합체 및 이의 용도 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
JP3462313B2 (ja) | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体dna及び変異型ウリカーゼの製造法 |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
CN1406140A (zh) | 2000-02-28 | 2003-03-26 | 吉倪塞思公司 | 纳米胶囊包封系统与方法 |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
KR101281775B1 (ko) | 2003-12-19 | 2013-07-15 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 소프트 또는 임프린트 리소그래피를 이용하여 분리된마이크로- 및 나노- 구조를 제작하는 방법 |
US7534448B2 (en) | 2004-07-01 | 2009-05-19 | Yale University | Methods of treatment with drug loaded polymeric materials |
EP2620157A3 (en) | 2007-10-12 | 2013-10-16 | Massachusetts Institute of Technology | Vaccine nanotechnology |
CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
WO2012149265A2 (en) * | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses |
KR20240119160A (ko) * | 2013-05-03 | 2024-08-06 | 셀렉타 바이오사이언시즈, 인크. | 바람직하지 않은 체액성 면역 반응을 감소시키기 위한 투약 조합물 |
WO2014179771A1 (en) * | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
PL3215133T3 (pl) | 2014-11-05 | 2021-06-14 | Selecta Biosciences, Inc. | Sposoby i kompozycje związane z zastosowaniem związków powierzchniowo czynnych o niskiej hlb do wytwarzania syntetycznych nanonośników zawierających rapalog |
-
2017
- 2017-03-11 LT LTEPPCT/US2017/021991T patent/LT3426285T/lt unknown
- 2017-03-11 PT PT177152980T patent/PT3426285T/pt unknown
- 2017-03-11 EP EP17715298.0A patent/EP3426285B1/en active Active
- 2017-03-11 CA CA3017365A patent/CA3017365A1/en active Pending
- 2017-03-11 HU HUE17715298A patent/HUE068144T2/hu unknown
- 2017-03-11 DK DK17715298.0T patent/DK3426285T3/da active
- 2017-03-11 AU AU2017230891A patent/AU2017230891B2/en active Active
- 2017-03-11 HR HRP20241127TT patent/HRP20241127T1/hr unknown
- 2017-03-11 ES ES17715298T patent/ES2986077T3/es active Active
- 2017-03-11 CN CN201780028609.1A patent/CN109152819A/zh active Pending
- 2017-03-11 WO PCT/US2017/021991 patent/WO2017156513A1/en active Application Filing
- 2017-03-11 BR BR112018068249A patent/BR112018068249A2/pt unknown
- 2017-03-11 IL IL318183A patent/IL318183A/en unknown
- 2017-03-11 PL PL17715298.0T patent/PL3426285T3/pl unknown
- 2017-03-11 JP JP2018548079A patent/JP7417354B2/ja active Active
- 2017-03-11 FI FIEP17715298.0T patent/FI3426285T3/fi active
- 2017-03-11 KR KR1020227029367A patent/KR20220123332A/ko not_active Ceased
- 2017-03-11 EP EP24177803.4A patent/EP4445955A3/en active Pending
- 2017-03-11 MX MX2018011012A patent/MX2018011012A/es unknown
- 2017-03-11 RS RS20240946A patent/RS65941B1/sr unknown
- 2017-03-11 US US15/456,520 patent/US20170258927A1/en not_active Abandoned
- 2017-03-11 KR KR1020187029146A patent/KR20180120753A/ko not_active Ceased
-
2018
- 2018-09-12 IL IL261700A patent/IL261700A/en unknown
-
2022
- 2022-01-27 JP JP2022011177A patent/JP7547402B2/ja active Active
-
2024
- 2024-04-15 JP JP2024065367A patent/JP2024102099A/ja active Pending
- 2024-07-15 AU AU2024204851A patent/AU2024204851A1/en not_active Abandoned
- 2024-08-29 US US18/818,714 patent/US20250090451A1/en active Pending
- 2024-10-31 US US18/933,195 patent/US20250057756A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3426285T3 (pl) | Formulacje i dawki pegylowanej urykazy | |
DK3688162T3 (da) | Formuleringer | |
EP3430731A4 (en) | IUGW ARCHITECTURE | |
EP3324978A4 (en) | Oligonucleotide compositions and methods thereof | |
MA49715A (fr) | Oligomères et conjugués d'oligomères | |
DK3235550T3 (da) | Forlystelse | |
ZA201904704B (en) | Topical cyclosporine-containing formulations and uses thereof | |
MA41794A (fr) | Agents thérapeutiques modifiés et compositions associées | |
EP3310376A4 (en) | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | |
IL263574A (en) | Calr and jak2 vaccine compositions | |
EP3541385A4 (en) | PHARMACEUTICAL FORMULATIONS | |
HUE055762T2 (hu) | Nyújtott hatású készítmények | |
EP3522872A4 (en) | Amlodipine formulations | |
MA44987A (fr) | Formulations de médicaments améliorées | |
DK3525897T3 (da) | Spilsystem | |
CL2018001733A1 (es) | Analogos cortistatinos y usos relacionados. | |
EP3697418A4 (en) | ENHANCED BROMOCRIPTINE FORMULATIONS | |
HUE063178T2 (hu) | Kopanlizib formulációi | |
EP3390348A4 (en) | DENDRIMER AND FORMULATIONS THEREFROM | |
DK3316856T3 (da) | Blandede formuleringer | |
EP3548425A4 (en) | NANOPARTICLE FORMULATIONS | |
EP3534963A4 (en) | FORMULATIONS OF PEGYLATED ARGININE DEIMINASE | |
EP3535386A4 (en) | ENDOTOXIN-FREE ASPARAGINASE | |
EP3416672A4 (en) | Oritavancin FORMULATIONS | |
FI3512518T3 (fi) | Hitaasti vapautuvia buprenorfiiniformulaatioita |